VERTEX PHARMACEUTICALS INC / MA Q3 FY2026 earnings call

Strategic Expansion & M&A:

• Completed the acquisition of Krenetics Pharmaceuticals, adding Palsonify (acromegaly) as the eighth commercialized medicine.
• Transitioned Charlie Wagner to Chief Operating Officer; Jonathan Poole will assume CFO role on January 1, 2027.

Pipeline Advancements:

• CF: Oliftrec is the leading therapy with once-daily dosing; submissions initiated for ages 2-5. Next-gen VX828 showed promise but results are mixed vs. Trikafta baseline; waiting on full NG3.0 data before pivotal decisions.
• Renal: POVI (IGAN) PDUFA date is November 30, 2026. Anaxipline (AMKD) completed enrollment in Amplitude trial; interim analysis expected early 2027.
• T1D: Prioritizing VX017 allogeneic cell therapy over other programs due to scalability and broader eligibility.

Commercial Execution:

• Oliftrec sales surpassed $1 billion YTD in the US. Jurnavix became the #1 prescribed branded oral analgesic in the US with >750,000 prescriptions in Q3.
• Palsonify achieved >40% brand share among initiators/switchers in acromegaly.
• Maintaining Patient Support Program (PSP) for Jurnavix through mid-2027 to ensure access during payer coverage expansion.

Total revenue grew 12% year-over-year to approximately $4.3 billion (implied by segment totals). Cystic Fibrosis (CF) generated $3.3 billion in revenue, representing 8% YoY growth and accounting for roughly 77% of total revenue. Hematology contributed $99 million from Casgevi. Pain management generated $58 million from Jurnavix. Rare Endocrinology contributed $24 million from Palsonify in Q3.

• Revenue: Raised full-year 2026 guidance to $13.15–$13.25 billion (from $13.1–$13.2 billion), driven by Krenetics integration ($40–$50M contribution).
• Gross Margin: Expects full-year gross margins slightly below 86%.
• Operating Expenses: Revised combined non-GAAP operating expense guidance up to ~$6 billion (from $5.65–$5.75 billion) to include ~$250 million in Krenetics costs.
• Non-Operating Costs: Expects ~$105 million in financing costs related to the Krenetics acquisition.
• Tax Rate: Full-year non-GAAP effective tax rate expected between 19.5% and 20.5%.

• Commercialization Risks: Potential impact of patient support program (PSP) sunset on Jurnavix net revenue if payer coverage does not fully materialize.
• Regulatory Risks: Citizen petitions regarding POVI labeling (IgG monitoring) and varying global regulatory expectations for EGFR endpoints (1-year vs. 2-year data).
• Clinical Development Risks: Uncertainty in selecting the best Next-Gen 3.0 CFTR modulator from the VX828/VX581/VX272 pipeline.
• Integration Risks: Execution risks associated with integrating Krenetics operations and culture.

Q: Analyst asked about POVI's IgG monitoring requirements following a citizen petition, specifically regarding infection rates and label implications. / A: CEO Reshma Kewalramani noted that opportunistic infections were 0%, and mild/moderate infection rates were balanced (0.5%) vs placebo. She emphasized that clinical trial data supports safety, and FDA conversations are ongoing ahead of the PDUFA date, indicating confidence in the current label approach without requiring restrictive IgG hold rules.

Q: Analyst asked what constitutes a 'win' for the Anaxipline Amplitude trial in AMKD regarding proteinuria and EGFR endpoints. / A: CEO clarified that while proteinuria is measured, the key endpoint for accelerated approval agreed upon with the FDA is a statistically significant improvement in GFR slope. She expressed high confidence in achieving this separation based on prior Phase 2 data showing substantial proteinuria reduction linked to GFR benefits.

Q: Analyst questioned the strategic decision to extend Jurnavix's Patient Support Program (PSP) into 2027 and its impact on revenue normalization. / A: CCO Duncan McKechnie explained that keeping the PSP active ensures patients without immediate payer coverage can still access the drug, supporting long-term prescription growth and practice conversion. He expects gross-to-net ratios to stabilize at 50-60% post-PSP sunset, aligning with mass-market brands, and anticipates revenue growth to continue commensurately.

Q: Analyst asked why Vertex decided to commit to collecting two-year EGFR data for POVI instead of using the one-year data acceptable to the FDA for US approval. / A: CEO stated the decision was made to facilitate global filings, as many ex-US regulators require two-year data. While the FDA accepts one-year data, Vertex aims for a worldwide launch, necessitating mature two-year efficacy data. Statistical handling of dropouts or cross-over patients will follow predefined plans accepted by global regulators.

Q: Analyst inquired about the competitive landscape for POVI uptake given existing BAF inhibitor usage and the trajectory of Oliftrec conversions. / A: CCO noted that while nephrologists are enthusiastic, many IGAN patients (approx. 163,000) remain untreated or under-treated. For CF, Oliftrec growth is driven by new rare mutation indications and international reimbursements rather than just switching. The company expects strong uptake for POVI due to its patient-centric auto-injector profile and unmet need in early-stage disease.